The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on March ....
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Minute windows have no benchmark: there is no intraday index history to compare against.
Potluri Laboratories Private Limited, one of the promoters of SMS Pharmaceuticals (holding 64.67% of total share capital), has created a Non-Disposal Undertaking (NDU) on 11,20,320 equity shares (1.32% of total share capital) of SMS Pharma. The encumbrance was created on 25 March 2025 in favour of Vistra ITCL (India) Limited as Debenture Trustee, with Avendus PE Investment Advisors (funds managed by Avendus) as the Debenture Holder. The shares are pledged as security for Non-Convertible Debentures (unrated, unlisted, secured, redeemable) issued by Potluri Laboratories itself. The value of encumbered shares is about Rs. 25.5 crore (at Rs. 227.65 per share), against a borrowing of Rs. 165 crore. The funds will be used for long-term strategic business objectives, working capital and general corporate purposes of Potluri Labs. The disclosure is filed under SEBI SAST Regulations 2011.
This is a routine promoter-level financing disclosure where the promoter is using its SMS Pharma shares as collateral for its own NCD issuance. At only 1.32% of total share capital and 1.32% of promoter holding, the encumbrance is small and unlikely to materially affect share price. However, investors should monitor aggregate promoter encumbrance levels across related promoter entities, as Hima Bindu Potluri separately has a larger pre-existing encumbrance of 12.55% of share capital.